Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Depreciation and Depletion: 2020-2025

Historic Depreciation and Depletion for C4 Therapeutics (CCCC) over the last 6 years, with Sep 2025 value amounting to $384,000.

  • C4 Therapeutics' Depreciation and Depletion rose 5.21% to $384,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year increase of 31.27%. This contributed to the annual value of $1.5 million for FY2024, which is 6.65% down from last year.
  • Per C4 Therapeutics' latest filing, its Depreciation and Depletion stood at $384,000 for Q3 2025, which was down 7.69% from $416,000 recorded in Q2 2025.
  • C4 Therapeutics' 5-year Depreciation and Depletion high stood at $545,000 for Q1 2023, and its period low was $128,000 during Q4 2023.
  • Its 3-year average for Depreciation and Depletion is $376,545, with a median of $375,000 in 2024.
  • Per our database at Business Quant, C4 Therapeutics' Depreciation and Depletion plummeted by 75.43% in 2023 and then skyrocketed by 184.38% in 2024.
  • Over the past 5 years, C4 Therapeutics' Depreciation and Depletion (Quarterly) stood at $323,000 in 2021, then skyrocketed by 61.30% to $521,000 in 2022, then tumbled by 75.43% to $128,000 in 2023, then soared by 184.38% to $364,000 in 2024, then climbed by 5.21% to $384,000 in 2025.
  • Its Depreciation and Depletion stands at $384,000 for Q3 2025, versus $416,000 for Q2 2025 and $364,000 for Q1 2025.